menu
    • menu

    Company profile for Vigil Neuroscience

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vigil‘s drug pipeline consists of therapeutic candidates targeting critical microglial signaling pathways in which loss-of-function mutations cause life-threatening neurodegenerative diseases. Microglia are multi-functional, specialized cells that act as sentinels to maintain brain function. In healthy brains, and during infection, aging, and disease, optimally performing microglia act to protect the brain against processe...
    Vigil‘s drug pipeline consists of therapeutic candidates targeting critical microglial signaling pathways in which loss-of-function mutations cause life-threatening neurodegenerative diseases. Microglia are multi-functional, specialized cells that act as sentinels to maintain brain function. In healthy brains, and during infection, aging, and disease, optimally performing microglia act to protect the brain against processes that can ultimately lead to neurodegeneration. We aim to restore and enhance the performance of these critical cells in disease settings where they are not performing optimally.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vigil NeuroscienceUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Technology Square, 8th floor Cambridge, MA 02139
    Telephone
    Telephone
    +1 857 254 4445
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.vigilneuro.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vigil-neuroscience/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi Completes the Acquisition of Vigil Neuroscience
    Sanofi Completes the Acquisition of Vigil Neuroscience

    06 Aug 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-08-06-05-00-00-3128014

    PRESS RELEASE
    06 Aug 2025
    Share Share
    Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Ph 2 Trial
    Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Ph 2 Trial

    05 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/04/3093434/0/en/Vigil-Neuroscience-Provides-Update-on-Iluzanebart-Phase-2-IGNITE-Trial-in-ALSP.html

    GLOBENEWSWIRE
    05 Jun 2025
    Share Share
    Sanofi to Acquire Vigil Neuroscience in $470M Deal
    Sanofi to Acquire Vigil Neuroscience in $470M Deal

    22 May 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-05-21-23-15-31-3086232

    PRESS RELEASE
    22 May 2025
    Share Share
    Vigil’s TREM2-Targeted Alzheimer’s Shows Early Promise
    Vigil’s TREM2-Targeted Alzheimer’s Shows Early Promise

    24 Jan 2025

    // BIOSPACE

    https://www.biospace.com/business/biogen-trims-research-workforce-higher-dose-sma-drug-accepted-for-regulatory-review

    BIOSPACE
    24 Jan 2025
    Share Share
    Vigil Announces FDA Has Removed Partial Clinical Hold on VG-3927
    Vigil Announces FDA Has Removed Partial Clinical Hold on VG-3927

    17 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/09/17/2947269/0/en/Vigil-Neuroscience-Announces-FDA-Has-Removed-Partial-Clinical-Hold-on-VG-3927.html

    GLOBENEWSWIRE
    17 Sep 2024
    Share Share
    Vigil Neuroscience to Present at Cantor Global Healthcare Conference
    Vigil Neuroscience to Present at Cantor Global Healthcare Conference

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/09/16/2947018/0/en/Vigil-Neuroscience-to-Present-at-Cantor-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search